One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients
Katsuhiro Ito, Yuki Kita, Takashi Kobayashi
doi : 10.1111/iju.15101
Editorial comment to real-world outcomes of pembrolizumab for platinum refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients
Yusuke Goto MD, PhD
doi : 10.1111/iju.15113
Optimization of first-line systemic therapy in patients with advanced clear cell renal cell carcinoma
Toshio Takagi
doi : 10.1111/iju.15103
Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study
Keita Izumi, Masaharu Inoue, Satoshi Washino, Suguru Shirotake, Makoto Kagawa, Hideki Takeshita, Yuji Miura, Yoji Hyodo, Masafumi Oyama, Satoru Kawakami, Tomoaki Miyagawa, Kazutaka Saito, Yukio Kageyama
doi : 10.1111/iju.15128
Editorial Comment on Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study
Takeshi Yuasa M.D., Ph.D.
doi : 10.1111/iju.15146
A comparative study on nivolumab and axitinib as secondary treatment in patients with metastatic renal cell carcinoma: A multi-institutional retrospective study in Japan
Taigo Kato, Satoru Yumiba, Wataru Nakata, Kosuke Nakano, Akira Nagahara, Kyosuke Matsuzaki, Yujiro Hayashi, Koji Hatano, Atsunari Kawashima, Tetsuya Takao, Kensaku Nishimura, Yasutomo Nakai, Masashi Nakayama, Kazuo Nishimura, Shingo Takada, Masao Tsujihata, Motohide Uemura, Norio Nonomura, Ryoichi Imamura
doi : 10.1111/iju.15130
Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab
Ryo Sato, Teruo Inamoto, Yuto Matsushita, Ayana Takemura, Taizo Uchimoto, Asuka Sano, Hiroki Tanaka, Gaku Ishikawa, Kyohei Watanabe, Hiromitsu Watanabe, Keita Tamura, Daisuke Motoyama, Takayuki Sugiyama, Atsushi Otsuka, Ken-ichi Harada, Haruhito Azuma, Hideaki Miyake
doi : 10.1111/iju.15133
Editorial Comment to Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab
Hiroaki Matsumoto M.D., Ph.D.
doi : 10.1111/iju.15169
Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab
Ikko Tomisaki, Mirii Harada, Shigeru Sakano, Michikazu Terado, Ryoichi Hamasuna, Shuji Harada, Hiroomi Matsumoto, Soichiro Akasaka, Yujiro Nagata, Akinori Minato, Ken-ichi Harada, Naohiro Fujimoto
doi : 10.1111/iju.15151
Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma
Takuto Hara, Junya Furukawa, Yusuke Shiraishi, Yasuyoshi Okamura, Yukari Bando, Tomoaki Terakawa, Kenichi Harada, Yuzo Nakano, Masato Fujisawa
doi : 10.1111/iju.15193
Editorial Comment on “Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma�
Jun Teishima MD, PhD
doi : 10.1111/iju.15210
Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma
Nami Tomiyama, Yoshihiko Tasaki, Shuzo Hamamoto, Yosuke Sugiyama, Taku Naiki, Toshiki Etani, Kazumi Taguchi, Nayuka Matsuyama, Yasuhito Sue, Yoshihisa Mimura, Kunihiro Odagiri, Yusuke Noda, Maria Aoki, Yoshinobu Moritoki, Satoshi Nozaki, Satoshi Kurokawa, Atsushi Okada, Noriyasu Kawai, Yoko Furukawa-Hibi, Takahiro Yasui
doi : 10.1111/iju.15198
Real-world effectiveness of nivolumab and subsequent therapy in Japanese patients with metastatic renal cell carcinoma (POST-NIVO study): 36-month follow-up results of a clinical chart review
Junji Yonese, Nobuyuki Hinata, Satoru Masui, Yasutomo Nakai, Suguru Shirotake, Ario Takeuchi, Teruo Inamoto, Masahiro Nozawa, Kosuke Ueda, Toru Etsunaga, Takahiro Osawa, Motohide Uemura, Go Kimura, Kazuyuki Numakura, Kazutoshi Yamana, Hideaki Miyake, Satoshi Fukasawa, Naoto Morishima, Hiroaki Ito, Hirotsugu Uemura … See fewer authors
doi : 10.1111/iju.15206
Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan
Ken-ichi Harada, Ryo Sato, Yukari Bando, Asuka Sano, Yuto Matsushita, Keita Tamura, Tomoaki Terakawa, Junya Furukawa, Naohiro Fujimoto, Masato Fujisawa, Hideaki Miyake
doi : 10.1111/iju.15230
Editorial Comment to Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan
Tsunenori Kondo M.D., Ph.D.
doi : 10.1111/iju.15256
The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion
Takuto Hara, Junya Furukawa, Yasuyoshi Okamura, Yukari Bando, Tomoaki Terakawa, Kenichi Harada, Satoru Takahashi, Yuzo Nakano, Masato Fujisawa
doi : 10.1111/iju.15231
Editorial Comment to “The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion�
Eiji Kikuchi MD, PhD, Nozomi Hayakawa MD, PhD
doi : 10.1111/iju.15257
Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study
Leandro Blas, Masaki Shiota, Hideaki Miyake, Masayuki Takahashi, Mototsugu Oya, Norihiko Tsuchiya, Naoya Masumori, Hideyasu Matsuyama, Wataru Obara, Nobuo Shinohara, Kiyohide Fujimoto, Masahiro Nozawa, Kojiro Ohba, Chikara Ohyama, Katsuyoshi Hashine, Shusuke Akamatsu, Tomomi Kamba, Koji Mita, Momokazu Gotoh, Shuichi Tatarano, Masato Fujisawa, Yoshihiko Tomita, Shoichiro Mukai, Keiichi Ito, Tokiyoshi Tanegashima, Shoji Tokunaga, Masatoshi Eto, SNiP-RCC Investigators
doi : 10.1111/iju.15265
Editorial Comment to Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP-RCC study
Hiroki Ishihara MD, PhD, Toshio Takagi MD, PhD
doi : 10.1111/iju.15269
Utility of prognostic prediction by early assessment of response to combined treatment with nivolumab plus ipilimumab in patients with treatment-naïve metastatic renal cell carcinoma
Ken-ichi Harada MD, PhD, Hideaki Miyake MD, PhD, Junya Furukawa MD, PhD, Naohiro Fujimoto MD, PhD, Masato Fujisawa MD, PhD
doi : 10.1111/iju.15144
